Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrolment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN) shares after opening at $16.29 moved to $17.16 on last trade day and at the end of the day closed at $14.19. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 10.42. Celladon Corp (NASDAQ:CLDN) showed a positive weekly performance of 22.43%.
On March 17, 2014, Fibrocell Science, Inc. (NYSEMKT:FCSC) issued a press release announcing the financial results for its fourth quarter and full year 2013. Fibrocell Science Inc. (NYSEMKT:FCSC) shares fell -6.45% in last trading session and ended the day on $5.80. Fibrocell Science Inc. (NYSEMKT:FCSC) return on equity ratio is recorded as -146.40% and its return on assets is -134.20%. Fibrocell Science Inc. (NYSEMKT:FCSC) yearly performance is 65.71%.
Investment analysts at Jefferies Group increased their target price on shares of NewLink Genetics Corp. (NASDAQ:NLNK) from $29.00 to $36.00 in a note issued to investors on Wednesday, American Banking News reports. Jefferies Group’s price objective would indicate a potential upside of 11.73% from the company’s current price. NewLink Genetics Corp (NASDAQ:NLNK) shares moved down -9.28% in last trading session and was closed at $27.96, while trading in range of $27.71 – $31.33. NewLink Genetics Corp (NASDAQ:NLNK) year to date (YTD) performance is 27.03%.
On March 13, 2014, Discovery Laboratories, Inc. (NASDAQ:DSCO) issued a press release highlighting the results of operations for the year and quarter ended December 31, 2013, and providing a business update. Discovery Laboratories, Inc. (NASDAQ:DSCO) weekly performance is -15.44%. On last trading day company shares ended up $2.19. Discovery Laboratories, Inc. (NASDAQ:DSCO) distance from 50-day simple moving average (SMA50) is -9.81%. Analysts mean target price for the company is $5.67.
Leave a Reply